cisplatin + gemcitabine

This combination chemotherapy regimen, consisting of cisplatin and gemcitabine, was specifically evaluated for intraperitoneal (IP) administration in a Phase I/II clinical trial led by Memorial Sloan Kettering Cancer Center. The regimen targets refractory or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers that have persisted after initial treatment. By delivering the agents directly into the peritoneal cavity, the treatment aims to maximize the exposure of tumor surfaces to high concentrations of chemotherapy while reducing systemic side effects. Cisplatin acts as a platinum-based alkylating agent that forms DNA cross-links, thereby inhibiting DNA replication and transcription. Gemcitabine, a pyrimidine nucleoside analog, functions as a prodrug that, once phosphorylated, inhibits DNA polymerase and ribonucleotide reductase, further compromising DNA synthesis and repair. This dual-action approach is intended to overcome resistance in advanced gynecological malignancies.

Other names

intraperitoneal cisplatin and gemcitabineIP cisplatin + IP gemcitabinechemotherapy-Memorial Sloan Kettering Cancer Center-ovarian cancer-fallopian tube cancer-primary peritoneal cavity cancer